<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of approach to lung cancer survivors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of approach to lung cancer survivors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of approach to lung cancer survivors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James Huang, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jamie Ostroff, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Larissa Nekhlyudov, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David E Midthun, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13357305"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Although lung cancer remains the leading cause of cancer mortality in individuals in the United States, advances in detection and treatment have increased the likelihood of long-term survival. In the United States, lung cancer is estimated to be diagnosed in approximately 240,000 people annually and causes almost 130,000 deaths [<a href="#rid1">1</a>]. Similarly, in the European Union in 2012, there were approximately 310,000 new cases and 265,000 deaths due to lung cancer [<a href="#rid2">2</a>]. Currently, there are an estimated 384,000 survivors of lung cancer in the United States, accounting for 4 percent of the adult cancer survivor population, and this number is increasing [<a href="#rid3">3</a>], attributable to advances in early detection (low-dose computed tomography scanning) and treatment. (See  <a class="medical medical_review" href="/d/html/7566.html" rel="external">"Screening for lung cancer"</a>.)</p><p>The issues facing cancer survivors and the approach to their management are discussed here. Overviews of lung cancer risk factors and initial evaluation and treatment are presented separately. (See  <a class="medical medical_review" href="/d/html/4641.html" rel="external">"Clinical manifestations of lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4639.html" rel="external">"Overview of the initial treatment and prognosis of lung cancer"</a>.)</p><p class="headingAnchor" id="H91768974"><span class="h1">DEFINITION OF A LUNG CANCER SURVIVOR</span><span class="headingEndMark"> — </span>The most widely accepted definition of a "cancer survivor" is a person who has been diagnosed with cancer, starting the day of their diagnosis until the end of life [<a href="#rid3">3</a>]. Within this broad definition, a long-term cancer survivor has been defined as a person who is living five years after diagnosis with or without disease [<a href="#rid4">4,5</a>].</p><p>For purposes of this discussion, lung cancer survivors are characterized as individuals who have been diagnosed with lung cancer and have completed all of their treatment for lung cancer. This topic will discuss the approach to lung cancer survivors and is focused on patients seen in a coordinated care setting between their primary care and oncology providers as well as those exclusively cared for by their primary care providers following treatment for lung cancer. These patients predominantly have had non-small cell lung cancer, since prolonged disease-free survival of patients with small cell lung cancer is much less common.</p><p class="headingAnchor" id="H76145289"><span class="h1">EPIDEMIOLOGY AND STAGING</span><span class="headingEndMark"> — </span>The term "lung cancer" refers to malignancies that originate in the airways or pulmonary parenchyma. Approximately 80 percent of all lung cancers are classified as non-small cell lung cancer (NSCLC), and most of the remainder are small cell lung cancer (SCLC). This distinction is required for proper staging, treatment, and prognosis. Smoking tobacco products is the primary cause of lung cancer; approximately 85 percent of lung cancer cases occur in current or former smokers. (See  <a class="medical medical_review" href="/d/html/4640.html" rel="external">"Cigarette smoking and other possible risk factors for lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4603.html" rel="external">"Pathology of lung malignancies"</a>.)</p><p>For patients with NSCLC, the Tumor, Node, Metastasis (TNM) staging system is used  (<a class="graphic graphic_table graphicRef109805" href="/d/graphic/109805.html" rel="external">table 1</a>). Although the TNM system can also be applied to SCLC, a simplified version that separates these patients into those with limited versus extensive disease is more widely used. The details of the staging system and the initial approach to establishing the diagnosis and extent of disease are discussed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4639.html" rel="external">"Overview of the initial treatment and prognosis of lung cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4602.html" rel="external">"Tumor, node, metastasis (TNM) staging system for lung cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4628.html" rel="external">"Pathobiology and staging of small cell carcinoma of the lung", section on 'Staging'</a>.)</p><p></p><p class="headingAnchor" id="H13357326"><span class="h1">ONCOLOGIC MANAGEMENT</span></p><p class="headingAnchor" id="H91769064"><span class="h2">Initial treatment</span><span class="headingEndMark"> — </span>The initial management of a patient with lung cancer depends heavily upon whether the tumor is a small cell (SCLC) or non-small cell lung cancer (NSCLC). For patients with NSCLC, management is based upon the extent of disease, as well as the patient's age, treatment preferences, and comorbid conditions. (See  <a class="medical medical_review" href="/d/html/4639.html" rel="external">"Overview of the initial treatment and prognosis of lung cancer", section on 'NSCLC'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who present with localized disease and without evidence of mediastinal lymph node involvement (stage I and stage II  (<a class="graphic graphic_table graphicRef109805" href="/d/graphic/109805.html" rel="external">table 1</a>)), surgical resection offers the best opportunity for long-term survival and cure in patients with resectable NSCLC. Local ablative therapy, particularly stereotactic radiation therapy (RT) techniques, may be an appropriate alternative for patients who are not surgical candidates. Postoperative adjuvant chemotherapy may improve overall survival in patients at increased risk of disease recurrence. (See  <a class="medical medical_review" href="/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with mediastinal lymph node involvement (stage III disease) at presentation, a combined-modality approach using chemotherapy and RT with or without surgery is generally preferred. (See  <a class="medical medical_review" href="/d/html/4623.html" rel="external">"Management of stage III non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with distant metastases (stage IV disease) at presentation or who subsequently have a recurrence with disseminated disease following definitive therapy are generally treated with systemic therapy. This may include chemotherapy, molecularly targeted therapy, or immunotherapy depending upon the characteristics of the individual patient's tumor. In appropriately selected patients, these approaches may prolong survival or decrease disease symptoms without sacrificing quality of life. RT and surgery may also be useful for symptom palliation in some patients. (See  <a class="medical medical_review" href="/d/html/4607.html" rel="external">"Overview of the initial treatment of advanced non-small cell lung cancer"</a>.)</p><p></p><p>SCLC is a disseminated disease in most patients, even at presentation, and prolonged survival is achieved in only a small minority of patients. Thus, systemic chemotherapy is an integral part of the initial treatment; management may also include RT to the thorax or to the brain, depending upon the initial extent of disease. (See  <a class="medical medical_review" href="/d/html/4639.html" rel="external">"Overview of the initial treatment and prognosis of lung cancer", section on 'SCLC'</a>.)</p><p class="headingAnchor" id="H13357333"><span class="h1">SURVEILLANCE AFTER TREATMENT</span><span class="headingEndMark"> — </span>Close surveillance for survivors of lung cancer who have received definitive therapy has been endorsed by numerous society guidelines [<a href="#rid6">6-9</a>] because they remain at risk for recurrence of their disease and for the development of second primary lung cancers [<a href="#rid4">4,5,10</a>].</p><p class="headingAnchor" id="H1441568701"><span class="h2">Rationale</span><span class="headingEndMark"> — </span>Although there is no clear evidence demonstrating a survival benefit with surveillance after treatment for lung cancer, the rationale is to detect recurrent disease, a second primary lung cancer, or other smoking-related malignancy early enough so that an intervention can increase survival, offer curative retreatment, and/or improve quality of life [<a href="#rid11">11</a>].</p><p>Even with completely resected early-stage lung cancer, recurrence rates are high. (See  <a class="medical medical_review" href="/d/html/4639.html" rel="external">"Overview of the initial treatment and prognosis of lung cancer", section on 'Prognosis of NSCLC'</a> and  <a class="medical medical_review" href="/d/html/4639.html" rel="external">"Overview of the initial treatment and prognosis of lung cancer", section on 'Prognosis'</a>.)</p><p>Unfortunately, the majority of recurrences present at distant sites and have a poor prognosis, but a small proportion of patients do present with localized and potentially salvageable relapses. The majority of locoregional and distant recurrences occur within the first two years [<a href="#rid10">10,12</a>].</p><p class="headingAnchor" id="H3536055945"><span class="h2">Approach</span><span class="headingEndMark"> — </span>The approach to post-therapy surveillance, the efficacy of surveillance, and the management of recurrences are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer", section on 'Post-therapy surveillance'</a> and  <a class="medical medical_review" href="/d/html/4607.html" rel="external">"Overview of the initial treatment of advanced non-small cell lung cancer"</a>.)</p><p>The following approach draws upon recommendations from multiple guideline-setting groups [<a href="#rid6">6-9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>A <strong>history, physical examination</strong>, and <strong>chest computed tomography (CT) including the adrenals</strong>, preferably with intravenous contrast, are indicated every six months for at least the first two years to evaluate for recurrence, and annually thereafter to surveil for recurrence and for new cancers [<a href="#rid9">9</a>]; some guidelines have even recommended every-six-month follow-up for up to four years [<a href="#rid6">6</a>]. Fluorodeoxyglucose positron emission tomography (PET)/CT imaging should not be used for surveillance, and low-dose CT may be used for the annual assessment after year 2 [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1">Patients who have had lung cancer are also at increased risk of a second primary, particularly of the lung, and may benefit from early detection of a second primary as well as from detection of a local recurrence. Thus, continued follow-up beyond five years with low-dose CT screening is reasonable in patients who have no evidence of disease, since these individuals are at risk for a second primary lung cancer as well as for recurrence. (See  <a class="medical medical_review" href="/d/html/7566.html" rel="external">"Screening for lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4637.html" rel="external">"Multiple primary lung cancers"</a>.)</p><p></p><p class="bulletIndent1">The risk of a second primary lung cancer appears to be greater in smokers [<a href="#rid13">13</a>], although the data are conflicting. In a study of 2151 stage I adenocarcinomas, a second primary lung cancer developed in 10 percent of nonsmokers and 8 percent of smokers. There was no difference in the cumulative incidence rate of a second primary lung cancer between smokers and nonsmokers [<a href="#rid14">14</a>]. The vast majority of second primary lung cancers were detected at a curable stage. In a smaller study examining 569 patients with stage I non-small cell lung cancer (NSCLC), a second primary lung cancer developed in 9 percent of patients, although no second primaries occurred in the 44 patients who were never-smokers [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients are also at risk for the development of second smoking-related malignancies at other sites. These cancers may arise at a wide range of primary sites [<a href="#rid16">16</a>], and the primary care provider should have a low threshold to obtain diagnostic imaging for unexplained symptoms. Survivors of stage I lung cancers who were current smokers at the time of diagnosis have a greater than threefold risk of developing second smoking-related malignancies (eg, head and neck, bladder), underscoring the critical importance of smoking cessation in these patients [<a href="#rid17">17</a>]. (See <a class="local">'Persistent tobacco use'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have undergone curative-intent treatment for stage I to III NSCLC, clinicians should not use brain magnetic resonance imaging (MRI) for routine surveillance; however, for those who have undergone curative-intent treatment for limited-stage small cell lung cancer, brain MRI every three months for the first year and every six months for the second year should be offered for surveillance for new or recurrent brain metastases [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Circulating biomarkers should not be used as a surveillance strategy for detection of recurrence [<a href="#rid9">9</a>].</p><p></p><p>Although immunotherapy has had a significant impact on the treatment of advanced lung cancer, it has not affected surveillance recommendations in cancer survivors.</p><p class="headingAnchor" id="H13357417"><span class="h2">Potential harms of surveillance</span><span class="headingEndMark"> — </span>One should also be mindful that<strong> </strong>patients undergoing routine surveillance imaging are subject to radiation exposure, the potential risks of false-positive results, and the anxiety associated with each test. However, the theoretical risk from radiation exposure, particularly from low-dose scans as has been recommended for surveillance, is generally accepted given the potential for identification of second malignancies at a curable state in this high-risk population [<a href="#rid6">6,14,17,18</a>]. Furthermore, false-positive results lead to complications in fewer than 0.4 percent of patients undergoing routine surveillance among lung cancer survivors, comparable to the rate seen among patients in the population undergoing CT screening for lung cancer [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a>.)</p><p class="headingAnchor" id="H76146736"><span class="h1">COMPLICATIONS OF TREATMENT AND LATE EFFECTS</span><span class="headingEndMark"> — </span>Long-term effects of treatment in lung cancer survivors revolve around complications from surgery, chemotherapy, immunotherapy, and/or radiation.</p><p class="bulletIndent1"><span class="glyph">●</span>Sequelae from surgery most commonly can include chronic pain (including post-thoracotomy pain syndrome), dyspnea, and, less frequently, the need for supplemental oxygen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Common long-term sequelae from chemotherapy include neuropathy and hearing loss, as well as neurocognitive changes. (See  <a class="medical medical_review" href="/d/html/2826.html" rel="external">"Overview of neurologic complications of platinum-based chemotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunotherapy has been associated with a range of autoimmune-related adverse events, including dermatologic, gastrointestinal, and endocrinologic side effects. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation can cause skin changes, radiation pneumonitis, esophagitis, and cardiovascular disease. These and other complications of treatment and late effects can result in long-term psychosocial sequelae and diminished quality of life. (See  <a class="medical medical_review" href="/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a> and  <a class="medical medical_review" href="/d/html/4331.html" rel="external">"Radiation-induced lung injury"</a>.)</p><p></p><p class="headingAnchor" id="H13357431"><span class="h1">SYMPTOMS</span><span class="headingEndMark"> — </span>Lung cancer survivors commonly report post-treatment symptoms such as pain, dyspnea, distressed mood, sleep impairment, neuropathy [<a href="#rid20">20</a>], and fatigue, which negatively impact quality of life [<a href="#rid6">6-8,12,21,22</a>]. Although some of these symptoms will gradually improve within 6 to 12 months after initial treatment, impairments in quality of life, psychological functioning [<a href="#rid23">23</a>], and physical functioning may persist for several years [<a href="#rid6">6-8,12,16,24-26</a>].</p><p class="headingAnchor" id="H13357439"><span class="h2">Fatigue, dyspnea, pain</span><span class="headingEndMark"> — </span>Lung cancer survivors frequently report a variety of physical symptoms, including fatigue, dyspnea, pain, coughing, insomnia, impaired cognitive function, and psychological distress [<a href="#rid27">27-31</a>]. These can contribute to a sedentary lifestyle and decreased functioning ability [<a href="#rid3">3,32</a>]. Nearly 80 percent of lung cancer survivors report some difficulty with a physical symptom, and this is clinically significant in approximately 30 percent of lung cancer survivors [<a href="#rid29">29,33</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Fatigue is one of the most common postsurgical symptoms reported by lung cancer survivors (up to 90 percent in some studies) [<a href="#rid3">3,4</a>]. Fatigue is linked to depression, anxiety, chronic pain, psychological distress, dyspnea, and sleep disturbances [<a href="#rid3">3,34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea is also common in lung cancer survivors [<a href="#rid35">35,36</a>]. The American Thoracic Society suggests the prevalence ranges from 55 to 87 percent in all stages of lung cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic pain has also been reported in approximately 50 percent of lung cancer survivors, specifically after a thoracotomy [<a href="#rid37">37</a>]. Approximately one-half of lung cancer patients report inadequate pain control, and nearly 40 percent of long-term lung cancer survivors report chronic pain symptoms [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lobectomies and bilobectomies have been associated with significant declines in sleep, mental function, sexual activity, and overall health-related quality of life, even years postresection [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who undergo chemotherapy tend to report symptoms leading to a decreased quality of life. Side effects associated with chemotherapy can occur in patients regardless of sex, age, or stage of cancer [<a href="#rid4">4,28,39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chemotherapy-induced peripheral neuropathy is a common treatment side effect and can cause severe pain and changes in heart rate and blood pressure, and in more severe cases paralysis or organ failure [<a href="#rid40">40-42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunotherapy is increasingly being used as treatment for recurrent disease, and has been associated with durable remissions in a significant number of cases. Such treatment is associated with a range of immune-mediated toxicities that include dermatologic toxicities, diarrhea/colitis, hepatotoxicity, and endocrinopathies, although other sites can also be affected. (See  <a class="medical medical_review" href="/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation"</a> and  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is evidence of health disparities along racial, ethnic, and sociodemographic lines for physical health symptoms. Survivors who report African American and Hispanic race, low socioeconomic status, and low education are more likely to report worse physical health outcomes and less physical activity [<a href="#rid43">43,44</a>].</p><p></p><p class="headingAnchor" id="H13357446"><span class="h2">Psychological distress</span><span class="headingEndMark"> — </span>Psychological distress is common. Up to 80 percent of lung cancer survivors experience psychological distress, and this rate is three times more common than observed among survivors of other types of cancers [<a href="#rid3">3</a>]. Although the causes of heightened distress in lung cancer survivorship are largely unknown, it may be associated in part with the poor prognosis and perceived stigma attached to this disease [<a href="#rid45">45,46</a>].</p><p>Psychological distress can include symptoms of generalized fear; specific fear of recurrence, sadness, worry, or uncertainty; stress, including relationship stress; poor sleep quality; lack of concentration; depression; anxiety; suicidal ideations; and survivor's guilt [<a href="#rid47">47-49</a>]. Emotional and psychological distress cause negative changes in social and cognitive functioning. Among lung cancer survivors, heightened anxiety is correlated with an increase in physical symptoms and a decrease in overall functioning [<a href="#rid3">3</a>].</p><p>Research suggests that psychosocial interventions can reduce distress in lung cancer patients, but mental health services are generally under-utilized [<a href="#rid30">30</a>]. Clinicians treating survivors of lung cancer might consider routine screening for depression (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.uspreventiveservicestaskforce.org%2FHome%2FGetFileByID%2F218&amp;token=UBVAQSeX8y0zcV1Zya7Dmk8miLU8OlvXKuJCF73%2FxXLfL%2BxbGTKkDdzl0363dQM7G%2FHI8rlcSBOixP58rz8chWZ%2BV2wrZzsjbprRRrO0jH0%3D&amp;TOPIC_ID=14233" target="_blank">PHQ-9</a>), anxiety (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.thenationalcouncil.org%2Fintegrated-health-coe%2F&amp;token=aPNWlCBQZ3jJ9Km8%2BIhrlgsY9%2FpqC9BEQD5RZBh3SpdkE9rgG639T1l1SXSadP8F3fSDjxCYt107EZyQKj9%2FtA%3D%3D&amp;TOPIC_ID=14233" target="_blank">GAD</a>), and/or psychological distress (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nccn.org%2Fdocs%2Fdefault-source%2Fpatient-resources%2Fnccn_distress_thermometer.pdf%3Fsfvrsn%3Def1df1a2_4&amp;token=LWNmAMmOszTGcuX6c0Ea1KGkRyScGnN593o%2B4o6p0Qh5I%2FDCukr61OHUpKYmaC9nPKja8Ybfwasnmal1WXYAYp6svhjJ%2FpB6xdgiS1RJXR8MBFvCfMFZ%2Fku9JD%2F9Pxp8&amp;TOPIC_ID=14233" target="_blank">Distress Thermometer</a>). (See  <a class="medical medical_review" href="/d/html/83887.html" rel="external">"Screening for depression in adults"</a> and  <a class="medical medical_review" href="/d/html/496.html" rel="external">"Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis", section on 'Diagnostic criteria'</a>.)</p><p>There is evidence of geographic and racial and ethnic disparities in mental health outcomes such as depression, anxiety, quality of life, and distress between lung cancer survivors living in rural areas as compared with survivors living in urban areas, and in racial and ethnic underrepresented groups as compared with White survivors. Lung cancer survivors in rural communities, those who are in racial and ethnic underrepresented groups, and those who have low socioeconomic status may experience poor post-treatment mental health for a variety of reasons, including limited access to mental health services, fewer socioeconomic resources, and limited access to a support network of other lung cancer survivors [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H13357453"><span class="h2">Stigma</span><span class="headingEndMark"> — </span>Given that lung cancer is highly linked with tobacco smoking, lung cancer patients report that others tend to assume they are at fault for getting lung cancer [<a href="#rid51">51</a>]. Stigma is more strongly associated with lung cancer than other cancers. Stigma can have a negative effect on lung cancer patients' psychological well-being and has been associated with anxiety and depression. Perceived stigma can lead to social isolation and avoidance, which sometimes discourages patients from seeking medical care and psychosocial support [<a href="#rid51">51,52</a>]. There is growing recognition of the need for multilevel interventions to prevent and mitigate stigma experienced by lung cancer patients/survivors [<a href="#rid53">53,54</a>].</p><p class="headingAnchor" id="H13357460"><span class="h2">Cognitive impairment</span><span class="headingEndMark"> — </span>More than one-half of cancer survivors report cognitive difficulties, which are believed to be the result of various treatments, and can persist for decades, significantly impacting quality of life [<a href="#rid55">55</a>]. Many cancer survivors describe subjective difficulties with attention, concentration, and short-term memory. Both surgery [<a href="#rid56">56</a>] and chemotherapy [<a href="#rid57">57-59</a>] are associated with cognitive decline in non-small cell lung cancer (NSCLC) patients. Some data suggest that chemotherapy, specifically <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> [<a href="#rid60">60</a>], commonly used in the treatment of lung cancer patients, can contribute to cognitive deterioration [<a href="#rid61">61</a>].</p><p>Unfortunately, brain metastases are common in both NSCLC and small cell lung cancer (SCLC). In addition to the symptoms brain metastases may cause, radiation therapy may contribute to cognitive impairment. Prophylactic cranial radiation may lead to chronic neurotoxicity and impaired cognitive functioning in patients with SCLC [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Neurocognitive effects'</a>.)</p><p>A pilot study found that 35 percent of NSCLC patients showed impaired performance in at least one cognitive domain, and that a significant number of NSCLC patients (20 percent) experienced increased depression and anxiety associated with perceived cognitive impairment [<a href="#rid61">61</a>]. However, most of their symptoms resolved after receiving psychotherapy.</p><p class="headingAnchor" id="H13357467"><span class="h2">Sexual dysfunction</span><span class="headingEndMark"> — </span>More than 60 percent of cancer survivors report having long-term sexual dysfunction; however, fewer than 25 percent seek help [<a href="#rid63">63</a>]. Sexual concerns are prevalent in lung cancer survivors, although this is less frequent than with gynecologic or genitourinary cancers, and sexual dysfunction in female cancer patients remains underdiagnosed and undertreated [<a href="#rid64">64,65</a>]. Lung cancer survivors receive significantly less information on this topic than patients with cancers involving sexual organs, such as the prostate or ovaries [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/100080.html" rel="external">"Overview of sexual dysfunction in male cancer survivors"</a> and  <a class="medical medical_review" href="/d/html/17009.html" rel="external">"Overview of sexual dysfunction in female cancer survivors"</a> and  <a class="medical medical_review" href="/d/html/5485.html" rel="external">"Overview of sexual dysfunction in females: Management", section on 'Cancer survivors'</a>.)</p><p>Shortness of breath, fatigue, and emotional distress have been indicated as contributing factors for sexual functioning problems in lung cancer survivors [<a href="#rid65">65,67</a>]. Additionally, lung cancer patients report problems with sexual desire, erectile function, orgasm, frequency of sexual activity, body image, and communication about sex [<a href="#rid67">67</a>] that worsens during treatment [<a href="#rid63">63</a>] and remains problematic even after completion of lung cancer treatment [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H76146243"><span class="h1">ADDRESSING RISK BEHAVIORS</span></p><p class="headingAnchor" id="H2957592557"><span class="h2">Persistent tobacco use</span><span class="headingEndMark"> — </span>In non-small cell lung cancer (NSCLC) survivors, persistent smoking after diagnosis is associated with poor outcomes [<a href="#rid3">3,69-71</a>], including treatment complications, treatment-related toxicity, decreased overall quality of life, and decreased adherence to treatment. Along with advanced tumor stage, current smoking is a poor prognostic factor for lung cancer patients [<a href="#rid72">72</a>].</p><p>Patients who continue to smoke after diagnosis are more likely to develop secondary cancers and have higher rates of cancer- and noncancer-related mortality [<a href="#rid73">73,74</a>]. After surgical resection with curative intent, second tumors are 2.3 times more common and recurrent tumors are 1.9 times more common in patients who continue to smoke. Overall mortality in smokers is 2.9 times higher [<a href="#rid70">70</a>]. Drug metabolism can also be affected by current smoking. Finally, lung cancer patients who quit at the time of initial diagnosis report improved quality of life compared with those patients who continue smoking [<a href="#rid70">70</a>].</p><p>Despite the known health risks, smoking is prevalent among survivors of lung cancer. Based on a large population-based survey, 39 percent of lung cancer patients reported smoking at the time of diagnosis, and 14 percent reported smoking at five months postdiagnosis [<a href="#rid75">75</a>].</p><p>Unfortunately, long-term cessation is not an easy goal to achieve. Even patients who quit prior to surgery can have high relapse rates. For example, in one study, nearly 40 percent of smokers who quit before surgery relapsed during the postoperative period [<a href="#rid76">76</a>]. Lung cancer patients who are significantly more likely to be persistent smokers include those who have Medicare or other public insurance, are not having chemotherapy, are not having surgery, have prior cardiovascular disease, have lower body mass index (BMI), have less emotional support, and have higher daily smoking rates [<a href="#rid75">75</a>].</p><p>As lung cancer patients are diagnosed at earlier, more curable stages, smoking cessation is even more relevant and critical. All health care providers treating lung cancer survivors should adhere to the National Comprehensive Cancer Network guidelines for smoking cessation, including assessment of current tobacco use, advising current smokers to quit, and providing or referring current smokers to evidence-based, pharmacologic, and behavioral tobacco treatment. (See  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p>Although clinicians who care for lung cancer patients recognize the importance of tobacco cessation as a necessary part of clinical care, many still do not routinely provide assistance to their patients. A survey of thoracic oncology care providers showed that over 90 percent believe that current smoking affects clinical outcomes and that cessation should be a standard part of clinical care [<a href="#rid77">77</a>]. Although 90 percent of thoracic oncology providers asked patients about tobacco use and 81 percent advised patients to quit, only 40 percent discussed cessation medication options and 39 percent actively provided cessation assistance. Increasing tobacco cessation will require increased assessment and cessation at diagnosis and during follow-up, increased clinician education, and improved tobacco cessation methods. There is strong consensus that greater attention to tobacco dependence and delivery of evidence-based smoking cessation treatment are essential for high-quality cancer care [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H3790608436"><span class="h2">Diet</span><span class="headingEndMark"> — </span>There is limited research on the role of diet in the care of lung cancer survivors. There are also relationships between tobacco use and dietary patterns that introduce the potential for significant bias and confounding in these analyses. However, higher rates of fruit and vegetable consumption are consistently associated with reduced risk of lung cancer among both smoking and nonsmoking populations [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H4110978794"><span class="h2">Weight</span><span class="headingEndMark"> — </span>Limited evidence suggests higher baseline weight and weight gain during treatment are correlated with improved outcomes in lung cancer. Given that smoking is associated with lower body weight and with poor outcomes in lung cancer, it is not clear whether there are any true relationships between body weight and lung cancer outcomes, but some evidence has suggested that those who are underweight may experience worsened surgical outcomes for resectable NSCLC.</p><p>The International Lung Cancer Consortium conducted a retrospective analysis with 25,430 NSCLC patients from 16 studies to evaluate the association between BMI and lung cancer survival outcomes. Those who were underweight with a BMI of &lt;18.5 kg/m<sup>2</sup> or morbidly overweight with a BMI of &gt;40 kg/m<sup>2</sup> at the time of diagnosis had poorer survival outcomes, across clinical demographics. However, those who were slightly overweight with a BMI of 25 to ≤30 kg/m<sup>2</sup> had improved survival outcomes [<a href="#rid80">80</a>].</p><p>In a retrospective analysis of over 1500 patients with resected lung cancer, surgical resection-related mortality was 2.9 percent among those who were underweight, 0.6 percent among normal-weight individuals, 1.7 percent among those who were overweight, and 0 percent in persons with obesity [<a href="#rid81">81</a>].</p><p>Weight gain during treatment may be a surrogate for clinical outcomes or of smoking cessation, which is often accompanied by weight gain. In an analysis of 92 stage IIIB NSCLC patients treated with definitive split-course chest radiation and concurrent platinum-containing chemotherapy, patients in the highest quartile of weight gain (&gt;4.5 pounds) had an improved three-year survival rate relative to those who did not achieve this level of weight gain (55 versus 31 percent). Weight gain was the only significant predictor of survival in multivariate analysis [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H1142925653"><span class="h2">Physical activity</span><span class="headingEndMark"> — </span>Physical activity among lung cancer survivors is low, both shortly after the end of the treatment [<a href="#rid83">83</a>] and years after treatment [<a href="#rid84">84</a>]. A growing number of studies have suggested that preoperative exercise programs may improve surgical outcomes and shorten length of hospital stay after lung resection in lung cancer patients [<a href="#rid85">85</a>], suggesting that lung cancer survivors may benefit from rehabilitation programs and/or encouragement to be more physically active [<a href="#rid86">86,87</a>].</p><p>Long-term lung cancer survivors who report more physical activity reported significantly better quality of life in all five measured domains (mental, physical, emotional, social, spiritual), less difficulty with symptom control, and decreased pain severity compared with those who were not physically active [<a href="#rid88">88</a>]. Older individuals and those lung cancer survivors that experienced surgical complications have reported less engagement in walking and other moderately strenuous activities. Evidence shows that exercise is safe and effective at improving physical fitness and muscle strength both before and after treatment for NSCLC survivors [<a href="#rid89">89</a>] and should be encouraged for sedentary lung cancer survivors. Given that many of these patients have cardiac and pulmonary comorbidities, cardiopulmonary rehabilitation may also be helpful before or after surgery. (See  <a class="medical medical_review" href="/d/html/14222.html" rel="external">"The roles of diet, physical activity, and body weight in cancer survivors", section on 'Physical activity'</a>.)</p><p class="headingAnchor" id="H2921680"><span class="h2">Financial toxicity/employment implications</span><span class="headingEndMark"> — </span>Financial worries may add to the stress experienced by patients with lung cancer and their caregivers. Given the demands of treatment, many patients diagnosed and treated for lung cancer will not return to work. Among cancer patients employed at the time of diagnosis, employees with lung cancer had the longest duration of disability absence. In addition, they are two to three times more likely to be unemployed after treatment. Evidence shows that those with low incomes who are from marginalized communities face greater challenges returning to work. [<a href="#rid90">90,91</a>].</p><p class="headingAnchor" id="H2921701"><span class="h2">Family</span><span class="headingEndMark"> — </span>Lung cancer and its treatment are challenging for patients and their caregivers. Many caregivers of patients with lung cancer experience negative physical and mental health effects of caregiving, whereas relations with family members improve for a substantial minority of caregivers. Despite reporting improved relations, caregivers and family members have reported challenges coping with the late effects of treatment and establishing a new normal [<a href="#rid20">20,92,93</a>].</p><p>These positive and negative consequences of caregiving should be considered when developing post-treatment interventions for this population. Distressed caregivers of lung cancer patients typically underuse mental health services, yet a sizable minority are interested in receiving professional assistance with psychosocial and practical needs [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H76145191"><span class="h1">COORDINATION OF CARE</span><span class="headingEndMark"> — </span>The care of lung cancer survivors requires coordination among various providers, which include oncology specialists (surgeon, medical oncologist, and/or radiation oncologist) and primary care specialists. Access to mental health clinicians with expertise in the psychosocial support of cancer survivors is also likely to promote adaptation to the challenges associated with lung cancer survivorship. Lung cancer survivors are likely to have comorbid chronic medical conditions, largely attributable to their older age and the high prevalence of smoking history in this group. The most common comorbid conditions are cardiovascular and pulmonary diseases, and survivors with comorbid pulmonary disease are likely to report a sedentary lifestyle and impairment in post-treatment quality of life [<a href="#rid9">9,21,95</a>].</p><p>The care of the lung cancer survivor must take into account multiple concerns. Management of treatment-related symptoms, side effects, and sequelae from surgery, radiation therapy, and/or chemotherapy are generally best handled by the treating clinician. However, lung cancer survivors are often older and many have chronic comorbid conditions. These may be more suitably managed by their primary care providers (PCPs), who may have long-standing relationships with their patients. Cancer surveillance can be conducted by either the PCP or the treating cancer specialist, as long as one adheres to the recommended regimens and timely consultations are sought if suspicious findings develop.</p><p>The coordination of care between those responsible for the original lung cancer treatment and the PCP, therefore, is of the utmost importance. While the surgeon, radiation oncologist, or medical oncologist may be particularly attuned to the issues of treatment and cancer surveillance, they may not be capable of providing sufficient attention to health behavior modification or chronic symptom management. On the other hand, the PCP may provide better preventative care but not be familiar with the management of lung cancer and the sequelae of cancer therapy. (See  <a class="medical medical_review" href="/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers"</a>.)</p><p class="headingAnchor" id="H76145210"><span class="h2">Nurse practitioner model</span><span class="headingEndMark"> — </span>Some have advocated bridging the divide between oncology providers and PCPs with dedicated nurses or nurse practitioners (NPs). A randomized trial of nurse-led follow-up of lung cancer patients versus conventional medical follow-up found that nurse-led follow-up was feasible and reported higher patient satisfaction with the nurse care model. Patient acceptability of nurse-led follow-up was high (75 percent), and there were no differences in survival or disease progression in the two groups [<a href="#rid96">96</a>].</p><p>Similar acceptance was found among 655 patients in an NP-led survivorship program at a large cancer center, where 92 percent of patients in the program elected to remain in the care of the NP rather than return to their thoracic surgeon [<a href="#rid97">97</a>]. An important feature of this model is the close coordination between the survivorship NP and the thoracic surgeon. The importance of surgeon input in the interpretation of surveillance imaging was highlighted in one study demonstrating an accuracy rate of 88 percent when scans reported as abnormal by the radiologist were evaluated by the surgeon [<a href="#rid98">98</a>]. This NP-based model has been shown to have high satisfaction as well as being cost-effective in other cancer populations, such as breast cancer [<a href="#rid99">99</a>].</p><p>Indicating need for greater continuing education, a survey examined awareness of long-term effects of chemotherapy across 1130 oncologists and 1072 PCPs and found that only 6 percent of PCPs were aware of the major long-term effects of four common chemotherapy agents compared with 65 percent of oncologists [<a href="#rid100">100</a>].</p><p>Regardless of the follow-up model used, close attention to treatment-related symptoms, chronic comorbidities, and cancer surveillance for both recurrence and the development of second malignancies must be paid to provide optimal care for the lung cancer survivor.</p><p class="headingAnchor" id="H4253520807"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112231.html" rel="external">"Society guideline links: Diagnosis and management of lung cancer"</a>.)</p><p class="headingAnchor" id="H13357488"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Lung cancer survivors are at risk for recurrence of their original cancer, for the development of second primary lung cancers, and for the development of other cancers, particularly those related to smoking. Thus, close surveillance is required for survivors in an effort to detect such malignancies at an early stage. (See <a class="local">'Surveillance after treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A history, physical examination, and chest computed tomography (CT) including the adrenals, preferably with intravenous contrast, are indicated every six months for at least the first two years to evaluate for recurrence, and annually thereafter to surveil for recurrence and for new cancers. Continued follow-up beyond five years with low-dose CT screening is reasonable in patients who have no evidence of disease, since these individuals are at risk for a second primary lung cancer as well as for recurrence. (See <a class="local">'Approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung cancer survivors commonly report post-treatment symptoms such as pain, dyspnea, distressed mood, sleep impairment, and fatigue even after their initial treatment, which negatively impact quality of life. In addition, lung cancer survivors are likely to have comorbid chronic medical conditions. (See <a class="local">'Symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Smoking cessation is indicated both to decrease the risk of a second primary malignancy and to reduce comorbidity. Patients should receive cessation counseling, advice, and pharmacotherapy. (See <a class="local">'Persistent tobacco use'</a> above and  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The coordination of care between those providing the original lung cancer treatment and the primary care provider (PCP) is of the utmost importance. Management of treatment-related symptoms, side effects, and sequelae from surgery, radiation therapy, and/or chemotherapy is generally handled by the treating clinician. However, chronic comorbid conditions may be more suitably managed by PCPs who have long-standing relationships with their patients. (See <a class="local">'Coordination of care'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.</a></li><li><a class="nounderline abstract_t">Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49:1374.</a></li><li><a class="nounderline abstract_t">Pozo CL, Morgan MA, Gray JE. Survivorship issues for patients with lung cancer. Cancer Control 2014; 21:40.</a></li><li><a class="nounderline abstract_t">Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. Methods Mol Biol 2009; 471:469.</a></li><li><a class="nounderline abstract_t">Clark MM, Novotny PJ, Patten CA, et al. Motivational readiness for physical activity and quality of life in long-term lung cancer survivors. Lung Cancer 2008; 61:117.</a></li><li><a class="nounderline abstract_t">Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012; 144:33.</a></li><li><a class="nounderline abstract_t">Colt HG, Murgu SD, Korst RJ, et al. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e437S.</a></li><li><a class="nounderline abstract_t">Vansteenkiste J, Crinò L, Dooms C, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 2014; 25:1462.</a></li><li><a class="nounderline abstract_t">Schneider BJ, Ismaila N, Aerts J, et al. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. J Clin Oncol 2020; 38:753.</a></li><li><a class="nounderline abstract_t">Virgo KS, McKirgan LW, Caputo MC, et al. Post-treatment management options for patients with lung cancer. Ann Surg 1995; 222:700.</a></li><li><a class="nounderline abstract_t">Stirling RG, Chau C, Shareh A, et al. Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis. J Thorac Oncol 2021; 16:784.</a></li><li><a class="nounderline abstract_t">Lou F, Sima CS, Rusch VW, et al. Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer. Ann Thorac Surg 2014; 98:1755.</a></li><li><a class="nounderline abstract_t">Boyle JM, Tandberg DJ, Chino JP, et al. Smoking history predicts for increased risk of second primary lung cancer: a comprehensive analysis. Cancer 2015; 121:598.</a></li><li><a class="nounderline abstract_t">Ripley RT, McMillan RR, Sima CS, et al. Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma. Ann Thorac Surg 2014; 98:968.</a></li><li><a class="nounderline abstract_t">Rice D, Kim HW, Sabichi A, et al. The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Ann Thorac Surg 2003; 76:1001.</a></li><li><a class="nounderline abstract_t">Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995; 109:120.</a></li><li><a class="nounderline abstract_t">Shiels MS, Gibson T, Sampson J, et al. Cigarette smoking prior to first cancer and risk of second smoking-associated cancers among survivors of bladder, kidney, head and neck, and stage I lung cancers. J Clin Oncol 2014; 32:3989.</a></li><li><a class="nounderline abstract_t">Lou F, Huang J, Sima CS, et al. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg 2013; 145:75.</a></li><li><a class="nounderline abstract_t">Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012; 307:2418.</a></li><li><a class="nounderline abstract_t">Fitch MI. Exploring Experiences of Survivors and Caregivers Regarding Lung Cancer Diagnosis, Treatment, and Survivorship. J Patient Exp 2020; 7:193.</a></li><li><a class="nounderline abstract_t">Younes RN, Gross JL, Deheinzelin D. Follow-up in lung cancer: how often and for what purpose? Chest 1999; 115:1494.</a></li><li><a class="nounderline abstract_t">Calman L, Beaver K, Hind D, et al. Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis. J Thorac Oncol 2011; 6:1993.</a></li><li><a class="nounderline abstract_t">Gudenkauf LM, Clark MM, Novotny PJ, et al. Spirituality and Emotional Distress Among Lung Cancer Survivors. Clin Lung Cancer 2019; 20:e661.</a></li><li><a class="nounderline abstract_t">Walsh GL, O'Connor M, Willis KM, et al. Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg 1995; 60:1563.</a></li><li><a class="nounderline abstract_t">Westeel V, Choma D, Clément F, et al. Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg 2000; 70:1185.</a></li><li><a class="nounderline abstract_t">Harpole DH Jr, Herndon JE 2nd, Young WG Jr, et al. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995; 76:787.</a></li><li><a class="nounderline abstract_t">Hechtner M, Eichler M, Wehler B, et al. Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study. J Thorac Oncol 2019; 14:420.</a></li><li><a class="nounderline abstract_t">Hoffman AJ, Given BA, von Eye A, et al. Relationships among pain, fatigue, insomnia, and gender in persons with lung cancer. Oncol Nurs Forum 2007; 34:785.</a></li><li><a class="nounderline abstract_t">Lowery AE, Krebs P, Coups EJ, et al. Impact of symptom burden in post-surgical non-small cell lung cancer survivors. Support Care Cancer 2014; 22:173.</a></li><li><a class="nounderline abstract_t">Yates P, Schofield P, Zhao I, Currow D. Supportive and palliative care for lung cancer patients. J Thorac Dis 2013; 5 Suppl 5:S623.</a></li><li><a class="nounderline abstract_t">Lowe M, Molassiotis A. A longitudinal qualitative analysis of the factors that influence patient distress within the lung cancer population. Lung Cancer 2011; 74:344.</a></li><li><a class="nounderline abstract_t">Solberg Nes L, Liu H, Patten CA, et al. Physical activity level and quality of life in long term lung cancer survivors. Lung Cancer 2012; 77:611.</a></li><li><a class="nounderline abstract_t">Brown JK, Cooley ME, Chernecky C, Sarna L. A symptom cluster and sentinel symptom experienced by women with lung cancer. Oncol Nurs Forum 2011; 38:E425.</a></li><li><a class="nounderline abstract_t">Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev 2019; 28:1563.</a></li><li><a class="nounderline abstract_t">Feinstein MB, Krebs P, Coups EJ, et al. Current dyspnea among long-term survivors of early-stage non-small cell lung cancer. J Thorac Oncol 2010; 5:1221.</a></li><li><a class="nounderline abstract_t">Hung R, Krebs P, Coups EJ, et al. Fatigue and functional impairment in early-stage non-small cell lung cancer survivors. J Pain Symptom Manage 2011; 41:426.</a></li><li><a class="nounderline abstract_t">Polański J, Jankowska-Polańska B, Mazur G, Chabowski M. Strategies of Coping with Pain: Differences Associated with the Histological Type of Lung Cancer. Adv Exp Med Biol 2019; 1222:43.</a></li><li><a class="nounderline abstract_t">Ilonen IK, Räsänen JV, Knuuttila A, et al. Quality of life following lobectomy or bilobectomy for non-small cell lung cancer, a two-year prospective follow-up study. Lung Cancer 2010; 70:347.</a></li><li><a class="nounderline abstract_t">Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 2014; 22:2261.</a></li><li><a class="nounderline abstract_t">Zajączkowska R, Kocot-Kępska M, Leppert W, et al. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci 2019; 20.</a></li><li><a class="nounderline abstract_t">Gordon-Williams R, Farquhar-Smith P. Recent advances in understanding chemotherapy-induced peripheral neuropathy. F1000Res 2020; 9.</a></li><li><a class="nounderline abstract_t">Fradkin M, Batash R, Elmaleh S, et al. Management of Peripheral Neuropathy Induced by Chemotherapy. Curr Med Chem 2019; 26:4698.</a></li><li><a class="nounderline abstract_t">Pisu M, Kenzik KM, Oster RA, et al. Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: another long-term effect of cancer? Cancer 2015; 121:1257.</a></li><li><a class="nounderline abstract_t">Philip EJ, Coups EJ, Feinstein MB, et al. Physical activity preferences of early-stage lung cancer survivors. Support Care Cancer 2014; 22:495.</a></li><li><a class="nounderline abstract_t">Shen MJ, Hamann HA, Thomas AJ, Ostroff JS. Association between patient-provider communication and lung cancer stigma. Support Care Cancer 2016; 24:2093.</a></li><li><a class="nounderline abstract_t">Riley KE, Ulrich MR, Hamann HA, Ostroff JS. Decreasing Smoking but Increasing Stigma? Anti-tobacco Campaigns, Public Health, and Cancer Care. AMA J Ethics 2017; 19:475.</a></li><li><a class="nounderline abstract_t">Yun YH, Kim YA, Sim JA, et al. Prognostic value of quality of life score in disease-free survivors of surgically-treated lung cancer. BMC Cancer 2016; 16:505.</a></li><li><a class="nounderline abstract_t">Zaorsky NG, Zhang Y, Tuanquin L, et al. Suicide among cancer patients. Nat Commun 2019; 10:207.</a></li><li><a class="nounderline abstract_t">Perloff T, King JC, Rigney M, et al. Survivor guilt: The secret burden of lung cancer survivorship. J Psychosoc Oncol 2019; 37:573.</a></li><li><a class="nounderline abstract_t">Annangi S, Nutalapati S, Foreman MG, et al. Potential Racial Disparities Using Current Lung Cancer Screening Guidelines. J Racial Ethn Health Disparities 2019; 6:22.</a></li><li><a class="nounderline abstract_t">Brown C, Cataldo J. Explorations of lung cancer stigma for female long-term survivors. Nurs Inq 2013; 20:352.</a></li><li><a class="nounderline abstract_t">Chambers SK, Dunn J, Occhipinti S, et al. A systematic review of the impact of stigma and nihilism on lung cancer outcomes. BMC Cancer 2012; 12:184.</a></li><li><a class="nounderline abstract_t">Hamann HA, Ver Hoeve ES, Carter-Harris L, et al. Multilevel Opportunities to Address Lung Cancer Stigma across the Cancer Control Continuum. J Thorac Oncol 2018; 13:1062.</a></li><li><a class="nounderline abstract_t">Banerjee SC, Haque N, Schofield EA, et al. Oncology Care Provider Training in Empathic Communication Skills to Reduce Lung Cancer Stigma. Chest 2021; 159:2040.</a></li><li><a class="nounderline abstract_t">Lange M, Joly F, Vardy J, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol 2019; 30:1925.</a></li><li><a class="nounderline abstract_t">Handy JR Jr. Minimally invasive lung surgery and postoperative quality of life. Thorac Surg Clin 2012; 22:487.</a></li><li><a class="nounderline abstract_t">Whitney KA, Lysaker PH, Steiner AR, et al. Is"chemobrain" a transient state? A prospective pilot study among persons with non-small cell lung cancer. J Support Oncol 2008; 6:313.</a></li><li><a class="nounderline abstract_t">Cerulla Torrente N, Navarro Pastor JB, de la Osa Chaparro N. Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy. J Cancer Surviv 2020; 14:464.</a></li><li><a class="nounderline abstract_t">Zhang Y, Chen YC, Hu L, et al. Chemotherapy-induced functional changes of the default mode network in patients with lung cancer. Brain Imaging Behav 2020; 14:847.</a></li><li><a class="nounderline abstract_t">Ongnok B, Chattipakorn N, Chattipakorn SC. Doxorubicin and cisplatin induced cognitive impairment: The possible mechanisms and interventions. Exp Neurol 2020; 324:113118.</a></li><li><a class="nounderline abstract_t">Kang HL, Chen VC, Hung WL, et al. Preliminary comparison of neuropsychological performance in patients with non-small-cell lung cancer treated with chemotherapy or targeted therapy. Neuropsychiatr Dis Treat 2019; 15:753.</a></li><li><a class="nounderline abstract_t">Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 81:77.</a></li><li><a class="nounderline abstract_t">Schover LR. Sexual quality of life in men and women after cancer. Climacteric 2019; 22:553.</a></li><li><a class="nounderline abstract_t">Del Pup L, Villa P, Amar ID, et al. Approach to sexual dysfunction in women with cancer. Int J Gynecol Cancer 2019; 29:630.</a></li><li><a class="nounderline abstract_t">Reese JB, Shelby RA, Abernethy AP. Sexual concerns in lung cancer patients: an examination of predictors and moderating effects of age and gender. Support Care Cancer 2011; 19:161.</a></li><li><a class="nounderline abstract_t">Flynn KE, Reese JB, Jeffery DD, et al. Patient experiences with communication about sex during and after treatment for cancer. Psychooncology 2012; 21:594.</a></li><li><a class="nounderline abstract_t">Flynn KE, Jeffery DD, Keefe FJ, et al. Sexual functioning along the cancer continuum: focus group results from the Patient-Reported Outcomes Measurement Information System (PROMIS®). Psychooncology 2011; 20:378.</a></li><li><a class="nounderline abstract_t">Hung MS, Chen YC, Huang TY, et al. Erectile Dysfunction After Surgical Treatment of Lung Cancer: Real-World Evidence. Clin Epidemiol 2020; 12:977.</a></li><li><a class="nounderline abstract_t">Toll BA, Brandon TH, Gritz ER, et al. Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. Clin Cancer Res 2013; 19:1941.</a></li><li><a class="nounderline abstract_t">Andreas S, Rittmeyer A, Hinterthaner M, Huber RM. Smoking cessation in lung cancer-achievable and effective. Dtsch Arztebl Int 2013; 110:719.</a></li><li><a class="nounderline abstract_t">Cooley ME, Sipples RL, Murphy M, Sarna L. Smoking cessation and lung cancer: oncology nurses can make a difference. Semin Oncol Nurs 2008; 24:16.</a></li><li><a class="nounderline abstract_t">Guo NL, Tosun K, Horn K. Impact and interactions between smoking and traditional prognostic factors in lung cancer progression. Lung Cancer 2009; 66:386.</a></li><li><a class="nounderline abstract_t">Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010; 340:b5569.</a></li><li><a class="nounderline abstract_t">Warren GW, Sobus S, Gritz ER. The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. Lancet Oncol 2014; 15:e568.</a></li><li><a class="nounderline abstract_t">Park ER, Japuntich SJ, Rigotti NA, et al. A snapshot of smokers after lung and colorectal cancer diagnosis. Cancer 2012; 118:3153.</a></li><li><a class="nounderline abstract_t">Cooley ME, Sarna L, Kotlerman J, et al. Smoking cessation is challenging even for patients recovering from lung cancer surgery with curative intent. Lung Cancer 2009; 66:218.</a></li><li><a class="nounderline abstract_t">Warren GW, Marshall JR, Cummings KM, et al. Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients. J Thorac Oncol 2013; 8:543.</a></li><li><a class="nounderline abstract_t">Croyle RT, Morgan GD, Fiore MC. Addressing a Core Gap in Cancer Care - The NCI Moonshot Program to Help Oncology Patients Stop Smoking. N Engl J Med 2019; 380:512.</a></li><li><a class="nounderline abstract_t">Clinton SK, Giovannucci EL, Hursting SD. The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions. J Nutr 2020; 150:663.</a></li><li><a class="nounderline abstract_t">Shepshelovich D, Xu W, Lu L, et al. Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. J Thorac Oncol 2019; 14:1594.</a></li><li><a class="nounderline abstract_t">Matsunaga T, Suzuki K, Imashimizu K, et al. Body Mass Index as a Prognostic Factor in Resected Lung Cancer: Obesity or Underweight, Which Is the Risk Factor? Thorac Cardiovasc Surg 2015; 63:551.</a></li><li><a class="nounderline abstract_t">Sher DJ, Gielda BT, Liptay MJ, et al. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer 2013; 14:370.</a></li><li><a class="nounderline abstract_t">Avancini A, Sartori G, Gkountakos A, et al. Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled? Oncologist 2020; 25:e555.</a></li><li><a class="nounderline abstract_t">Cavalheri V, Granger CL. Exercise training as part of lung cancer therapy. Respirology 2020; 25 Suppl 2:80.</a></li><li><a class="nounderline abstract_t">Steffens D, Beckenkamp PR, Hancock M, et al. Preoperative exercise halves the postoperative complication rate in patients with lung cancer: a systematic review of the effect of exercise on complications, length of stay and quality of life in patients with cancer. Br J Sports Med 2018; 52:344.</a></li><li><a class="nounderline abstract_t">Henshall CL, Allin L, Aveyard H. A Systematic Review and Narrative Synthesis to Explore the Effectiveness of Exercise-Based Interventions in Improving Fatigue, Dyspnea, and Depression in Lung Cancer Survivors. Cancer Nurs 2019; 42:295.</a></li><li><a class="nounderline abstract_t">Granger CL, McDonald CF, Berney S, et al. Exercise intervention to improve exercise capacity and health related quality of life for patients with Non-small cell lung cancer: a systematic review. Lung Cancer 2011; 72:139.</a></li><li><a class="nounderline abstract_t">Yoo JS, Yang HC, Lee JM, et al. The association of physical function and quality of life on physical activity for non-small cell lung cancer survivors. Support Care Cancer 2020; 28:4847.</a></li><li><a class="nounderline abstract_t">Edbrooke L, Granger CL, Denehy L. Physical activity for people with lung cancer. Aust J Gen Pract 2020; 49:175.</a></li><li><a class="nounderline abstract_t">Butow P, Laidsaar-Powell R, Konings S, et al. Return to work after a cancer diagnosis: a meta-review of reviews and a meta-synthesis of recent qualitative studies. J Cancer Surviv 2020; 14:114.</a></li><li><a class="nounderline abstract_t">Vayr F, Savall F, Bigay-Game L, et al. Lung cancer survivors and employment: A systematic review. Lung Cancer 2019; 131:31.</a></li><li><a class="nounderline abstract_t">Mosher CE, Given BA, Ostroff JS. Barriers to mental health service use among distressed family caregivers of lung cancer patients. Eur J Cancer Care (Engl) 2015; 24:50.</a></li><li><a class="nounderline abstract_t">Mosher CE, Ott MA, Hanna N, et al. Coping with physical and psychological symptoms: a qualitative study of advanced lung cancer patients and their family caregivers. Support Care Cancer 2015; 23:2053.</a></li><li><a class="nounderline abstract_t">Roddy MK, Flores RM, Burt B, Badr H. Lifestyle behaviors and intervention preferences of early-stage lung cancer survivors and their family caregivers. Support Care Cancer 2021; 29:1465.</a></li><li><a class="nounderline abstract_t">Kang J, Park EJ, Lee J. Cancer Survivorship in Primary Care. Korean J Fam Med 2019; 40:353.</a></li><li><a class="nounderline abstract_t">Moore S, Corner J, Haviland J, et al. Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial. BMJ 2002; 325:1145.</a></li><li><a class="nounderline abstract_t">Huang J, Logue AE, Ostroff JS, et al. Comprehensive long-term care of patients with lung cancer: development of a novel thoracic survivorship program. Ann Thorac Surg 2014; 98:955.</a></li><li><a class="nounderline abstract_t">Korst RJ, Kansler AL, Port JL, et al. Accuracy of surveillance computed tomography in detecting recurrent or new primary lung cancer in patients with completely resected lung cancer. Ann Thorac Surg 2006; 82:1009.</a></li><li><a class="nounderline abstract_t">Rosales AR, Byrne D, Burnham C, et al. Comprehensive survivorship care with cost and revenue analysis. J Oncol Pract 2014; 10:e81.</a></li><li><a class="nounderline abstract_t">Nekhlyudov L, Aziz NM, Lerro C, Virgo KS. Oncologists' and primary care physicians' awareness of late and long-term effects of chemotherapy: implications for care of the growing population of survivors. J Oncol Pract 2014; 10:e29.</a></li></ol></div><div id="topicVersionRevision">Topic 14233 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cancer statistics, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23485231" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24357740" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Survivorship issues for patients with lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109795" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology of lung cancer prognosis: quantity and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18243406" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Motivational readiness for physical activity and quality of life in long-term lung cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22710039" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23649451" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24562446" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31829901" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8526576" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Post-treatment management options for patients with lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33588110" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25110337" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25283893" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Smoking history predicts for increased risk of second primary lung cancer: a comprehensive analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25038021" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14529975" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The risk of second primary tumors after resection of stage I nonsmall cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7815787" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Incidence of local recurrence and second primary tumors in resected stage I lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25385740" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cigarette smoking prior to first cancer and risk of second smoking-associated cancers among survivors of bladder, kidney, head and neck, and stage I lung cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23127371" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22610500" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Benefits and harms of CT screening for lung cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32851140" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Exploring Experiences of Survivors and Caregivers Regarding Lung Cancer Diagnosis, Treatment, and Survivorship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10378539" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Follow-up in lung cancer: how often and for what purpose?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21892108" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31378618" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Spirituality and Emotional Distress Among Lung Cancer Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8787445" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Is follow-up of lung cancer patients after resection medically indicated and cost-effective?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11081867" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8625181" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30508641" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17723980" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Relationships among pain, fatigue, insomnia, and gender in persons with lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24018910" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Impact of symptom burden in post-surgical non-small cell lung cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24163753" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Supportive and palliative care for lung cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21511356" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A longitudinal qualitative analysis of the factors that influence patient distress within the lung cancer population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22681871" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Physical activity level and quality of life in long term lung cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22037342" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A symptom cluster and sentinel symptom experienced by women with lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31575553" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cancer Progress and Priorities: Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20592631" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Current dyspnea among long-term survivors of early-stage non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21216563" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fatigue and functional impairment in early-stage non-small cell lung cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31529288" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Strategies of Coping with Pain: Differences Associated with the Histological Type of Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20395012" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Quality of life following lobectomy or bilobectomy for non-small cell lung cancer, a two-year prospective follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24789421" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30909387" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mechanisms of Chemotherapy-Induced Peripheral Neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32201575" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Recent advances in understanding chemotherapy-induced peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30621553" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Management of Peripheral Neuropathy Induced by Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25564986" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: another long-term effect of cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24091722" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Physical activity preferences of early-stage lung cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26553030" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Association between patient-provider communication and lung cancer stigma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28553905" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Decreasing Smoking but Increasing Stigma? Anti-tobacco Campaigns, Public Health, and Cancer Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27439430" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prognostic value of quality of life score in disease-free survivors of surgically-treated lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30643135" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Suicide among cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30798776" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Survivor guilt: The secret burden of lung cancer survivorship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29729002" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Potential Racial Disparities Using Current Lung Cancer Screening Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23414179" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Explorations of lung cancer stigma for female long-term survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22607085" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A systematic review of the impact of stigma and nihilism on lung cancer outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29800746" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Multilevel Opportunities to Address Lung Cancer Stigma across the Cancer Control Continuum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33338443" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Oncology Care Provider Training in Empathic Communication Skills to Reduce Lung Cancer Stigma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31617564" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23084612" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Minimally invasive lung surgery and postoperative quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18847074" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Is"chemobrain" a transient state? A prospective pilot study among persons with non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32146576" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30617783" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Chemotherapy-induced functional changes of the default mode network in patients with lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31756316" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Doxorubicin and cisplatin induced cognitive impairment: The possible mechanisms and interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31015761" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Preliminary comparison of neuropsychological performance in patients with non-small-cell lung cancer treated with chemotherapy or targeted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20800380" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30380961" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sexual quality of life in men and women after cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30765487" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Approach to sexual dysfunction in women with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20820818" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sexual concerns in lung cancer patients: an examination of predictors and moderating effects of age and gender.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21394821" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Patient experiences with communication about sex during and after treatment for cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20878833" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Sexual functioning along the cancer continuum: focus group results from the Patient-Reported Outcomes Measurement Information System (PROMIS®).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32982462" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Erectile Dysfunction After Surgical Treatment of Lung Cancer: Real-World Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23570694" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24222790" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Smoking cessation in lung cancer-achievable and effective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18222148" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Smoking cessation and lung cancer: oncology nurses can make a difference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19304339" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Impact and interactions between smoking and traditional prognostic factors in lung cancer progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20093278" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439699" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271645" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A snapshot of smokers after lung and colorectal cancer diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321223" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Smoking cessation is challenging even for patients recovering from lung cancer surgery with curative intent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23529191" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30601710" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Addressing a Core Gap in Cancer Care - The NCI Moonshot Program to Help Oncology Patients Stop Smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31758189" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31163278" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26277079" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Body Mass Index as a Prognostic Factor in Resected Lung Cancer: Obesity or Underweight, Which Is the Risk Factor?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23260389" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32162811" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32567236" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Exercise training as part of lung cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29437041" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Preoperative exercise halves the postoperative complication rate in patients with lung cancer: a systematic review of the effect of exercise on complications, length of stay and quality of life in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29787385" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A Systematic Review and Narrative Synthesis to Explore the Effectiveness of Exercise-Based Interventions in Improving Fatigue, Dyspnea, and Depression in Lung Cancer Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21316790" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Exercise intervention to improve exercise capacity and health related quality of life for patients with Non-small cell lung cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31980896" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The association of physical function and quality of life on physical activity for non-small cell lung cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32233342" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Physical activity for people with lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31858379" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Return to work after a cancer diagnosis: a meta-review of reviews and a meta-synthesis of recent qualitative studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31027695" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Lung cancer survivors and employment: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24761985" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Barriers to mental health service use among distressed family caregivers of lung cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25527242" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Coping with physical and psychological symptoms: a qualitative study of advanced lung cancer patients and their family caregivers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32691229" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Lifestyle behaviors and intervention preferences of early-stage lung cancer survivors and their family caregivers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31779063" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Cancer Survivorship in Primary Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12433764" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25087931" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Comprehensive long-term care of patients with lung cancer: development of a novel thoracic survivorship program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16928526" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Accuracy of surveillance computed tomography in detecting recurrent or new primary lung cancer in patients with completely resected lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24065401" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Comprehensive survivorship care with cost and revenue analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24222054" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Oncologists' and primary care physicians' awareness of late and long-term effects of chemotherapy: implications for care of the growing population of survivors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
